Cartesian Therapeutics Q3 net loss narrows to $11.5 million from $35.9 million
Cartesian Therapeutics reported a third-quarter 2026 net loss of $11.5 million, or $0.38 per share, down from $35.9 million, or $1.38 per share, a year earlier. The narrower loss came mainly from a $10.7 million gain on the contingent value rights liability, while operating loss widened and revenue fell to zero, so the results are mixed for shareholders.
Key points
- Net loss was $11.5 million ($0.38 per share) versus $35.9 million ($1.38 per share) a year earlier; the CVR liability produced a $10.7 million gain, compared with a $16.9 million loss in the prior-year quarter.
- Operating loss widened to $25.0 million from $21.1 million, as research and development expenses rose to $15.6 million from $13.8 million and general and administrative expenses rose to $9.4 million from $7.7 million.
- Revenue was zero in the quarter, compared with $452,000 a year earlier.
- Cash, cash equivalents and restricted cash were $124.7 million at September 30, 2026, expected to support planned operations into 2028; Phase 3 AURORA data are expected in 1Q27 and a BLA is planned for mid-2027.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.